News Release
![]() |
<< Back |
![]() |
Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress
|
As the leading conference on antimicrobial resistance, the
About Cloudbreak
The Cloudbreak immunotherapy platform is a fundamentally new approach for the treatment of infectious disease that, in a single molecule, pairs potent antimicrobials with agents that redirect the immune system to destroy fungal, bacterial and viral pathogens. Cidara is initially developing Cloudbreak candidates for the treatment and prevention of serious multi-drug resistant (MDR) Gram-negative bacterial infections and viral infections. Different from traditional antibiotics or antivirals, the Cloudbreak ADCs physically link the pathogen and the immune component to eradicate or prevent pathogens via dual killing mechanisms.
About
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate, in a
Phase 3 clinical trial in the treatment of candidemia and invasive
candidiasis and plans to initiate a second Phase 3 trial in the
prophylaxis of invasive fungal infections. Rezafungin has improved
pharmacokinetics compared to existing echinocandins and the potential
for expanded utility across patient settings. It is the only once-weekly
product candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. Cidara also is leveraging
its novel Cloudbreak™ platform to develop antibody-drug conjugates for
the treatment of serious viral and Gram-negative bacterial infections.
Cloudbreak is the first immunotherapy discovery platform designed
specifically to create compounds that directly kill pathogens and also
direct a patient’s immune cells to attack and eliminate bacterial,
fungal or viral pathogens. Cidara is headquartered in
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the potential for the Cloudbreak immunotherapy
platform to treat and prevent serious multi-drug resistant Gram-negative
bacterial infections and viral infections and to fundamentally change
the treatment of infectious diseases. Risks that contribute to the
uncertain nature of the forward-looking statements include: the success
and timing of Cidara’s preclinical studies and clinical trials;
regulatory developments in
View source version on businesswire.com: https://www.businesswire.com/news/home/20181024005127/en/
Source:
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H.
Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com